|
Session 86
Poster Abstracts
Immune-Based Therapies
Wednesday, 1 - 4 pm
Poster Hall |
| 477 |
The TILT Trial - A Pilot Trial of ART Interruption with and without the Use of Interleukin-2
Brian Angus*1, F Lampe2, G Tambussi3, C Katlama4, M Youle2, I Williams5, B Clotet6, M Fisher7, F Post5, A Babiker8, and TILT trial steering committee
1John Radcliffe Hosp, Oxford, UK; 2Royal Free and Univ Coll London Med Sch, UK; 3Mario Negri Inst, Milan, Italy; 4Hosp Pitie-Salpetriere, Paris, France; 5King's Coll London, UK; 6Univ Hosp Germans Trias i Pujol, Barcelona, Spain; 7Royal Sussex County Hosp, Brighton, UK; and 8Med Res Council, London, UK |
| 478 |
Randomized, Controlled, Phase II Study with an MVA-Nef Vaccine in HIV-1-infected Patients with CD4 counts >250/µL followed by Structured Treatment Interruption
Thomas Harrer*1, J Hain2, J Vollmar2, N Baedeker2, V Sobek2, H Jaeger3, M Helm4, D Gorriahn5, L Schneider6, and E Harrer1
1Univ Hosp Erlangen, Germany; 2Bavarian Nordic GmbH, Martinsried, Germany; 3Practice Dr Jaeger, Munich, Germany; 4Practice M Helm, Nuremberg, Germany; 5Practice Dr Gorriahn, Munich, Germany; and 6Practice Dr Schneider, Fuerth, Germany |
479
 |
Generation of CTL with in vivo HIV-specific Immune Responses after Transduction of CD8+ T Cells with a Lentiviral Vector Encoding TCRalpha and beta Chains from HIV-specific CTL
Harris Goldstein*, J Zheng, A Follenzi, and A Joseph
Albert Einstein Coll of Med, Bronx, NY, US |
| 480 |
Multifunctional HIV-1-specific CD4 and CD8 T-cell Responses during a Therapeutic Immunization Study (QUEST) in HAART-treated Acutely Infected Subjects
Assia Samri*1, F Lampe2, B Autran1, A Phillips2, G Li-Anh3, R El-Habib4, T G5, S Kinloch de Loes2, and the QUEST Core and Study Groups
1INSERM U543, Hosp Pitie-Salpetriere, Paris, France; 2Royal Free and Univ Coll London, UK; 3GlaxoSmithKline, Greenford, UK; 4Sanofi Pasteur, France; and 5IRC USA |
481
|
Immunological Assessment of the Activity of a Therapeutic Vaccine during Analytical Treatment Interruption
Larissa Valor*1, J Navarro1, M Desco1, B Santamarķa1, C Rodriguez Sainz1, J Carbone1, J Gil1, D Podzamczer2, J Gonzalez Lahoz3, and E Fernandez-Cruz1
1Univ Gen Hosp Gregorio Maranon, Madrid, Spain; 2Ciudad Sanitaria Bellvitge, Barcelona, Spain; and 3Inst de Salud Carlos III, Madrid, Spain |
| 482 |
Improved Efficiency and Delivery of IL-15 DNA Vectors in Combination with IL-15 Receptor-a in Mice and Macaques Deliver a Potent Growth Signal for NK and T Cells
Cristina Bergamaschi*, R Jalah, M Rosati, A Valentin, V Kulkarni, C Alicea, V Patel, G M Zhang, B Felber, and G Pavlakis
NCI-Frederick, MD, US |
483
|
Deleterious Effects of NK Cells on CD4 T Cells during HIV Infection : A New Target for a Therapeutic Vaccine
V Vieillard1, D Costagliola2, J Strominger3, and Patrice Debre*1
1INSERM U543, Hosp Pitie-Salpetriere, Paris, France; 2INSERM U720, Hosp Pitie-Salpetriere, Paris, France; and 3Harvard Univ, Cambridge, MA, US |
484
|
Interleukin-7 Reduces the Levels of Spontaneous Apoptosis in CD4+ and CD8+ T Cells from HIV-1-infected Individuals
nfected Individuals
Lia Vassena*, M Proschan, A Fauci, and P Lusso
Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, US |
485
|
TheraVac-01: Evaluation of the Safety and Immunogenicity of the HIV-1 Vaccine NYVAC-B in Chronic HIV-1-infected Patients Successfully Treated with HAART in an Open-label Phase I Study
Pierre-Alexandre Bart*1, J Vermeulen2, A Harari1, G Tapia1, E Castro1, M Cavassini1, F Wit2, B Autran3, J Lange2, and G Pantaleo1
1Ctr Hosp Univ Vaudois Lausanne, Switzerland; 2Academic Med Ctr and Intl Antiviral Therapy Evaluation Ctr, Amsterdam, The Netherlands; and 3Faculty of Med, Univ Pierre and Marie Curie, Paris, France |
| 486 |
A Phase II, Randomized, Placebo-controlled Study to Evaluate the Immunogenicity of 2 Schedules of an Homologous Prime-boost with the ALVAC-HIV vCP1452 in Chronically HIV-infected Patients (MANON 02)
Christine Katlama*1, N Wincker2, D Costagliola1, R Tubiana1, R Murphy3, B Clotet4, J Gatell5, S Staszewski6, B Walker7, B Autran1, and ORVACS study group
1Hosp Pitie-Salpetriere, Paris, France; 2ORVACS, Paris, France; 3Northwestern University, Chicago, USA; 4Fndn irsiCaixa, Badalona, Spain; 5Hosp Clin Univ, Barcelona, Spain; 6JW Goethe Univ, Frankfurt, Germany; and 7Partners AIDS Res Ctr, Boston, MA, US |
|
